Quarterly Updates11 Feb 2026, 07:52 pm
Zim Laboratories' Q3 & 9M FY26 Financial Performance: 12.8% Growth in Total Operating Income
AI Summary
Zim Laboratories Limited has reported a 12.8% growth in Total Operating Income for Q3 FY26, reaching 31,087 Mn. However, the Total Operating Income for 9M FY26 declined by 0.4% to 32,691 Mn. The EBITDA for Q3 FY26 increased by 9.1% to 145 Mn, but declined by 15.5% for 9M FY26 to 280 Mn. The company invested 157 Mn in business expansion and registrations in Q3 FY26 and 9230 Mn in R&D spend for 9M FY26, accounting for 8.6% of the Total Operating Income.
Key Highlights
- 12.8% growth in Total Operating Income for Q3 FY26
- 0.4% decline in Total Operating Income for 9M FY26
- 9.1% increase in EBITDA for Q3 FY26
- 15.5% decline in EBITDA for 9M FY26
- 157 Mn invested in business expansion and registrations in Q3 FY26
- 9230 Mn invested in R&D spend for 9M FY26